Bausch + Lomb price target raised to $13 from $11 at BofA

BofA analyst Craig Bijou raised the firm’s price target on Bausch + Lomb (BLCO) to $13 from $11 and keeps an Underperform rating on the shares. Shares were up 13% in July before results as investors had grown more optimistic that a separation from Bausch Health (BHC) was getting closer, but B+L shares were down 8% over Wednesday to Friday of last week despite a Q2 beat and raise, the analyst noted. The firm still believes that “investor interest will be limited until there is more visibility on the separation,” the analyst added in a post-earnings note.